NCT03579433

Brief Summary

The purpose of the study was to evaluate the visual acuity outcomes when using the Optiwave Refractive Analysis (ORA) with VerifEye+ and Barrett Toric Calculator for calculating intraocular lens (IOL) power and axis in subjects requiring cataract surgery and implanted with a toric IOL in both eyes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
124

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

9 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 26, 2018

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 6, 2018

Completed
1 month until next milestone

Study Start

First participant enrolled

August 16, 2018

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 16, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 16, 2019

Completed
12 months until next milestone

Results Posted

Study results publicly available

April 7, 2020

Completed
Last Updated

April 7, 2020

Status Verified

April 1, 2020

Enrollment Period

8 months

First QC Date

June 26, 2018

Results QC Date

March 23, 2020

Last Update Submit

April 3, 2020

Conditions

Keywords

IOLIntraocular lensAstigmatismCataract Surgery

Outcome Measures

Primary Outcomes (1)

  • Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) of 20/20 or Better at Month 6

    Visual acuity (VA) was tested monocularly (each eye separately) using the correction obtained from the manifest refraction and 100% contrast electronic Early Treatment Diabetic Retinopathy Study (ETDRS) charts at a distance of 4 meters (m) from the eye. 20/20 represents normal distance eyesight. No hypothesis testing of the primary endpoint was specified.

    Month 6

Study Arms (2)

ORA with VerifEye+

EXPERIMENTAL

First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.

Device: ORA with VerifEye+Device: Acrysof® IQ Toric IOL

Barrett Toric Calculator

ACTIVE COMPARATOR

First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.

Other: Alcon Barrett Toric CalculatorDevice: Acrysof® IQ Toric IOL

Interventions

Intraoperative device that measures total corneal astigmatism in the aphakic condition and is used for the selection of IOL power. In the pseudophakic condition, ORA provides guidance for the alignment of the toric axis mark.

ORA with VerifEye+

Web-based software application that utilizes an algorithm (Barrett Formula) to estimate the amount of post-operative corneal astigmatism in order to optimize IOL model selection and axis placement, with interoperative axis alignment done manually.

Barrett Toric Calculator

Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)

Barrett Toric CalculatorORA with VerifEye+

Eligibility Criteria

Age22 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Planned cataract surgery with IOL implantation
  • Able to comprehend and sign the informed consent form
  • Preoperative astigmatism of 0.75 to 3.00 Diopter
  • Willing and able to complete all required postoperative visits

You may not qualify if:

  • Unclear intraocular media other than cataract
  • Pregnant or lactating
  • Presence or history of any condition or finding that makes the subject unsuitable as a candidate for cataract surgery or study participation or may confound the outcome of the study, in the opinion of the Investigator.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Alcon Investigative Site

Mt. Dora, Florida, 32757, United States

Location

Alcon Investigative Site

Panama City, Florida, 32405, United States

Location

Alcon Investigative Site

Poughkeepsie, New York, 12603, United States

Location

Alcon Investigative Site

Kingston, Pennsylvania, 18704, United States

Location

Alcon Investigative Site

Florence, South Carolina, 29501, United States

Location

Alcon Investigative Site

Mt. Pleasant, South Carolina, 29464, United States

Location

Alcon Investigative Site

Sioux Falls, South Dakota, 57108, United States

Location

Alcon Investigative Site

Nashville, Tennessee, 37205, United States

Location

Alcon Investigative Site

Nacogdoches, Texas, 75965, United States

Location

MeSH Terms

Conditions

CataractAstigmatism

Condition Hierarchy (Ancestors)

Lens DiseasesEye DiseasesRefractive Errors

Results Point of Contact

Title
Sr. CDMA Project Lead, Surgical
Organization
Alcon Research, LLC

Study Officials

  • Clinical Operations Lead, Surgical

    Alcon Research, LLC

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 26, 2018

First Posted

July 6, 2018

Study Start

August 16, 2018

Primary Completion

April 16, 2019

Study Completion

April 16, 2019

Last Updated

April 7, 2020

Results First Posted

April 7, 2020

Record last verified: 2020-04

Data Sharing

IPD Sharing
Will not share

Locations